Dr Kristin Brown
Head of Division
Board of Commitee
Peter Maccallum Cancer Centre
Australia
Biography
Dr is a team leader in the Cancer Therapeutics Program at the Peter MacCallum Cancer Centre and holds a joint appointment in the Department of Biochemistry and Molecular Biology at the University of Melbourne. Dr Brown received her BSc and MSc degrees from the University of Canterbury (New Zealand). Following the award of her PhD from the University of Otago (New Zealand) in 2009, Dr Brown undertook post-doctoral training with Prof Alex Toker at Beth Israel Deaconess Medical Center, Harvard Medical School. In 2013, Dr Brown was promoted to Instructor in Pathology at Harvard Medical School. Dr Brown relocated to Melbourne in 2016 to establish her research laboratory investigating mechanisms that drive response or resistance to chemotherapy and targeted therapy agents in breast cancer. This knowledge is applied to the pre-clinical development of novel and more effective Dr is a team leader in the Cancer Therapeutics Program at the Peter MacCallum Cancer Centre and holds a joint appointment in the Department of Biochemistry and Molecular Biology at the University of Melbourne. Dr Brown received her BSc and MSc degrees from the University of Canterbury (New Zealand). Following the award of her PhD from the University of Otago (New Zealand) in 2009, Dr Brown undertook post-doctoral training with Prof Alex Toker at Beth Israel Deaconess Medical Center, Harvard Medical School. In 2013, Dr Brown was promoted to Instructor in Pathology at Harvard Medical School. Dr Brown relocated to Melbourne in 2016 to establish her research laboratory investigating mechanisms that drive response or resistance to chemotherapy and targeted therapy agents in breast cancer. This knowledge is applied to the pre-clinical development of novel and more effective
Research Interest
research laboratory investigating mechanisms that drive response or resistance to chemotherapy and targeted therapy agents in breast cancer. This knowledge is applied to the pre-clinical development of novel and more effective